Lilly posts results for five completed Phase 1 studies, opens three new early trials

Eli Lilly posted results for five completed early-stage studies and registered three new Phase 1 trials this week.

• Orforglipron was tested against carbamazepine in a Phase 1 drug interaction study in healthy participants, assessing carbamazepine's effect on orforglipron blood levels and clearance, and safety when the two drugs were given alone or together.¹ No participants in the combination arm on Day 15 had serious adverse events (0/28).¹
• A Phase 1 bioequivalence study comparing orforglipron capsules and tablets in participants with obesity or overweight completed on June 2, 2025, with results posted July 17, 2026.² The study enrolled 533 participants.²
• A Phase 1 dose-titration study of LY3502970 in Chinese participants with obesity or overweight and weight-related comorbidities gave the drug or placebo orally and completed with results posted.³ Enrollment was 24 participants.³
• A Phase 1 single- and multiple-ascending dose study of LY3502970 in Japanese participants with type 2 diabetes evaluated side effects of the drug.⁴ The study enrolled 62 participants.⁴
• A completed crossover study compared pharmacokinetics of pegilodecakin delivered by pre-filled syringe versus vial in healthy adults.⁵ ARMO BioSciences is listed as a collaborator alongside lead sponsor Eli Lilly.
• A new Phase 1 study of LY4268989 (MORF-057) is recruiting healthy participants to compare two tablet formulations under different meal conditions.⁶ Enrollment is estimated at 50 participants.⁶
• A new Phase 1 open-label study is recruiting healthy participants to evaluate pharmacokinetics, safety and tolerability of two eloralintide solution formulations.⁷ Enrollment is estimated at 58 participants.⁷
• A new Phase 1 placebo-controlled single- and multiple-ascending dose study of LY4178256 is recruiting healthy participants to assess safety and tolerability.⁸ Enrollment is estimated at 88 participants.⁸